Seagen Inc. Insider Trading for May 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Seagen Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Seagen Inc. for May 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Grant | A | 0.00 | 1,335 | 0 | 56,598 | 55.3 K to 56.6 K (+2.42 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Simonian Nancy A | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Simonian Nancy A | Director | Grant | A | 0.00 | 1,335 | 0 | 26,098 | 24.8 K to 26.1 K (+5.39 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Seth Alpna | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Seth Alpna | Director | Grant | A | 0.00 | 1,335 | 0 | 10,048 | 8.7 K to 10 K (+15.32 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | Orwin John A | Director | Grant | A | 0.00 | 1,335 | 0 | 26,098 | 24.8 K to 26.1 K (+5.39 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | LIPPMAN MARC E | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | LIPPMAN MARC E | Director | Grant | A | 0.00 | 1,335 | 0 | 131,648 | 130.3 K to 131.6 K (+1.02 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | GRYSKA DAVID W | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | GRYSKA DAVID W | Director | Grant | A | 0.00 | 1,335 | 0 | 49,348 | 48 K to 49.3 K (+2.78 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | AKKARAJU SRINIVAS | Director | Grant | A | 0.00 | 1,335 | 0 | 41,503 | 40.2 K to 41.5 K (+3.32 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Grant | A | 0.00 | 3,444 | 0 | 56,019 | 52.6 K to 56 K (+6.55 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,335 | 0 | 43,290,171 | 43.3 M to 43.3 M (0.00 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,335 | 0 | 4,084,186 | 4.1 M to 4.1 M (+0.03 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 160.00 | 1,602,312 | 256,369,920 | 43,288,836 | 44.9 M to 43.3 M (-3.57 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 160.00 | 147,688 | 23,630,080 | 4,082,851 | 4.2 M to 4.1 M (-3.49 %) |
| May 14 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Option Exercise | M | 15.46 | 6,942 | 107,323 | 0 | |
| May 14 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Sell | S | 166.00 | 6,942 | 1,152,372 | 52,575 | 59.5 K to 52.6 K (-11.66 %) |
| May 14 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Buy | M | 15.46 | 6,942 | 107,323 | 59,517 | 52.6 K to 59.5 K (+13.20 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 1,100 | 13,200 | 85,419 | |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 3,549 | 42,588 | 86,519 | |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 5,355 | 64,260 | 90,068 | |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 8,204 | 98,448 | 95,423 | |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 10,264 | 123,168 | 103,627 | |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 163.50 | 1,100 | 179,850 | 718,339 | 719.4 K to 718.3 K (-0.15 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 1,100 | 13,200 | 719,439 | 718.3 K to 719.4 K (+0.15 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 162.68 | 3,549 | 577,351 | 718,339 | 721.9 K to 718.3 K (-0.49 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 3,549 | 42,588 | 721,888 | 718.3 K to 721.9 K (+0.49 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 161.74 | 5,355 | 866,118 | 718,339 | 723.7 K to 718.3 K (-0.74 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 5,355 | 64,260 | 723,694 | 718.3 K to 723.7 K (+0.75 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 160.72 | 8,204 | 1,318,547 | 718,339 | 726.5 K to 718.3 K (-1.13 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 8,204 | 98,448 | 726,543 | 718.3 K to 726.5 K (+1.14 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 160.02 | 10,264 | 1,642,445 | 718,339 | 728.6 K to 718.3 K (-1.41 %) |
| May 12 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 10,264 | 123,168 | 728,603 | 718.3 K to 728.6 K (+1.43 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Option Exercise | M | 15.46 | 6,942 | 107,323 | 6,942 | |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Sell | S | 163.02 | 6,942 | 1,131,667 | 52,575 | 59.5 K to 52.6 K (-11.66 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Buy | M | 15.46 | 6,942 | 107,323 | 59,517 | 52.6 K to 59.5 K (+13.20 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Option Exercise | M | 65.11 | 11,912 | 775,590 | 21,948 | |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Sell | S | 164.50 | 11,912 | 1,959,526 | 117,233 | 129.1 K to 117.2 K (-9.22 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Buy | M | 65.11 | 11,912 | 775,590 | 129,145 | 117.2 K to 129.1 K (+10.16 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 158.50 | 457,803 | 72,561,776 | 44,891,148 | 45.3 M to 44.9 M (-1.01 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 158.50 | 42,197 | 6,688,225 | 4,230,539 | 4.3 M to 4.2 M (-0.99 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.16 | 4,343 | 721,610 | 45,348,951 | 45.4 M to 45.3 M (-0.01 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.16 | 400 | 66,462 | 4,272,736 | 4.3 M to 4.3 M (-0.01 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.96 | 48,880 | 8,063,118 | 45,353,294 | 45.4 M to 45.4 M (-0.11 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.96 | 4,505 | 743,133 | 4,273,136 | 4.3 M to 4.3 M (-0.11 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.19 | 84,663 | 13,901,157 | 45,402,174 | 45.5 M to 45.4 M (-0.19 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.19 | 7,805 | 1,281,534 | 4,277,641 | 4.3 M to 4.3 M (-0.18 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 163.41 | 16,159 | 2,640,610 | 45,486,837 | 45.5 M to 45.5 M (-0.04 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 163.41 | 1,489 | 243,324 | 4,285,446 | 4.3 M to 4.3 M (-0.03 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.62 | 41,072 | 6,843,564 | 45,502,996 | 45.5 M to 45.5 M (-0.09 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.62 | 3,786 | 630,837 | 4,286,935 | 4.3 M to 4.3 M (-0.09 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 165.70 | 91,613 | 15,180,641 | 45,544,068 | 45.6 M to 45.5 M (-0.20 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 165.70 | 8,444 | 1,399,205 | 4,290,721 | 4.3 M to 4.3 M (-0.20 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.60 | 178,862 | 29,440,041 | 45,635,681 | 45.8 M to 45.6 M (-0.39 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.60 | 16,485 | 2,713,372 | 4,299,165 | 4.3 M to 4.3 M (-0.38 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.06 | 45,606 | 7,482,107 | 45,814,543 | 45.9 M to 45.8 M (-0.10 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.06 | 4,204 | 689,707 | 4,315,650 | 4.3 M to 4.3 M (-0.10 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 166.77 | 205 | 34,188 | 55,263 | 55.5 K to 55.3 K (-0.37 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 166.23 | 2,435 | 404,770 | 55,468 | 57.9 K to 55.5 K (-4.21 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 164.98 | 4,319 | 712,549 | 57,903 | 62.2 K to 57.9 K (-6.94 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 164.21 | 8,041 | 1,320,413 | 62,222 | 70.3 K to 62.2 K (-11.44 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 167.99 | 284 | 47,709 | 70,263 | 70.5 K to 70.3 K (-0.40 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 167.26 | 11,011 | 1,841,700 | 70,547 | 81.6 K to 70.5 K (-13.50 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 166.27 | 5,400 | 897,858 | 81,558 | 87 K to 81.6 K (-6.21 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | WELCH DANIEL G | Director | Sell | S | 165.62 | 3,305 | 547,374 | 86,958 | 90.3 K to 87 K (-3.66 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 166.55 | 2,400 | 399,720 | 718,339 | 720.7 K to 718.3 K (-0.33 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 165.77 | 12,656 | 2,097,985 | 720,739 | 733.4 K to 720.7 K (-1.73 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 164.55 | 6,400 | 1,053,120 | 733,395 | 739.8 K to 733.4 K (-0.87 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 163.77 | 3,946 | 646,236 | 739,795 | 743.7 K to 739.8 K (-0.53 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 167.67 | 4,297 | 720,478 | 743,741 | 748 K to 743.7 K (-0.57 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 167.06 | 6,700 | 1,119,302 | 748,038 | 754.7 K to 748 K (-0.89 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 165.44 | 6,432 | 1,064,110 | 754,738 | 761.2 K to 754.7 K (-0.85 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 164.80 | 7,169 | 1,181,451 | 761,170 | 768.3 K to 761.2 K (-0.93 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Sell | S | 166.11 | 2,000 | 332,220 | 52,575 | 54.6 K to 52.6 K (-3.66 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Sell | S | 166.23 | 3,056 | 508,006 | 54,575 | 57.6 K to 54.6 K (-5.30 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 20.06 | 8,500 | 170,510 | 9,000 | |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | AKKARAJU SRINIVAS | Director | Sell | S | 167.26 | 8,500 | 1,421,710 | 40,168 | 48.7 K to 40.2 K (-17.47 %) |
| May 07 2020 | SGEN | SEATTLE GENETICS I ... | AKKARAJU SRINIVAS | Director | Buy | M | 20.06 | 8,500 | 170,510 | 48,668 | 40.2 K to 48.7 K (+21.16 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 15.46 | 26,867 | 415,364 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 12.00 | 14,167 | 170,004 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 45.30 | 1,103 | 49,966 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 44.09 | 2,268 | 99,996 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 41.04 | 2,436 | 99,973 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 39.15 | 2,554 | 99,989 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 26.10 | 3,831 | 99,989 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 26.10 | 3,831 | 99,989 | 173,888 | 170.1 K to 173.9 K (+2.25 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 41.04 | 2,436 | 99,973 | 170,057 | 167.6 K to 170.1 K (+1.45 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 44.09 | 2,268 | 99,996 | 167,621 | 165.4 K to 167.6 K (+1.37 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 39.15 | 2,554 | 99,989 | 165,353 | 162.8 K to 165.4 K (+1.57 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 45.30 | 1,103 | 49,966 | 162,799 | 161.7 K to 162.8 K (+0.68 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 164.10 | 1,200 | 196,920 | 161,696 | 162.9 K to 161.7 K (-0.74 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 163.36 | 12,167 | 1,987,601 | 162,896 | 175.1 K to 162.9 K (-6.95 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 162.45 | 13,500 | 2,193,075 | 175,063 | 188.6 K to 175.1 K (-7.16 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 15.46 | 26,867 | 415,364 | 188,563 | 161.7 K to 188.6 K (+16.62 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 147.00 | 14,167 | 2,082,556 | 161,696 | 175.9 K to 161.7 K (-8.06 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 12.00 | 14,167 | 170,004 | 175,863 | 161.7 K to 175.9 K (+8.76 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | LIPPMAN MARC E | Director | Sell | S | 152.03 | 1,000 | 152,030 | 130,313 | 131.3 K to 130.3 K (-0.76 %) |